CN117355317A - Use of vaccinia virus-induced inflammation rabbit fur extract for treating demyelinating diseases of nervous system - Google Patents

Abstract

Use of vaccinia virus-induced inflammation rabbit fur extract in preparing medicine, more specifically, use in preparing medicine for treating nervous system demyelinating diseases. Furthermore, the use of vaccinia virus-induced inflammation rabbit fur extract for the preparation of a medicament for restoring nerve function in a patient suffering from a demyelinating disease of the nervous system. The demyelinating disease of the nervous system may be multiple sclerosis, acute disseminated encephalomyelitis or neuromyelitis optica. Furthermore, vaccinia virus-induced inflammation rabbit fur extract may be found to be readiness.

Description

Use of vaccinia virus-induced inflammation rabbit fur extract for treating demyelinating diseases of nervous system Technical Field

The invention belongs to the field of medicines. In particular, the invention relates to novel therapeutic uses of vaccinia virus-induced inflammatory rabbit fur extracts. More particularly, the invention relates to therapeutic uses of vaccinia virus-induced inflammatory rabbit fur extracts. More particularly, the invention relates to the medical use of vaccinia virus-induced inflammatory rabbit fur extracts for the treatment of neurological demyelinating diseases, in particular central nervous system demyelinating diseases. The demyelinating disease of the nervous system may be multiple sclerosis, acute disseminated encephalomyelitis or neuromyelitis optica.

Background

Nerve fibers are classified into unmyelinated nerve fibers and myelinated nerve fibers. Myelinated nerve fibers such as autonomic ganglion pre-fibers and larger somatic nerve fibers have an outer sheath on their axons, known as myelin sheath. Myelin is made up of the cell membranes of myelin cells. Myelin cells of the central nerve are oligodendrocytes. The myelin sheath of peripheral nerve fibers is made up of the cell membranes of schwann cells. Myelin, which is composed of lipids and proteins, protects axons and has an insulating effect on nerve impulses and accelerates the conduction of nerve impulses. The thick myelin sheath fiber impulse conduction is also fast. When myelin sheath is destroyed, conduction speed is slowed down. Nerve conduction is also affected by temperature, and an increase in body temperature can cause conduction block when myelination occurs.

Demyelinating diseases may include central nervous system demyelinating diseases and peripheral nervous system demyelinating diseases. The clinical common central nervous system demyelinating diseases comprise multiple sclerosis, acute disseminated encephalomyelitis, neuromyelitis optica and the like, the incidence rate of the central nervous system demyelinating diseases in recent years is in a year-by-year increasing trend, the quality of life of a patient is seriously influenced, and the physical and mental health of the patient is seriously threatened.

Multiple sclerosis (Multiple Sclerosis, MS) is a disease characterized mainly by inflammatory demyelinating lesions of the central nervous system white matter. The most frequently involved parts of the disease are white matter, optic nerve, spinal cord, brainstem and cerebellum, and the main clinical characteristics are the recurrence relief, the spatial multiple of symptoms and signs and the time multiple of the disease course which are presented by the white matter of the central nervous system in distributed multiple disease foci and disease courses. Multiple sclerosis was recorded in China, catalog for rare diseases of the first group, 2018.

Acute disseminated encephalomyelitis (Acute Disseminated Encephalomyelitis, ADEM) is one of the idiopathic central nervous system demyelinating diseases, seen in children, but can also occur at any age. ADEM is a first-occurring demyelinating disease affecting multiple areas of the central nervous system, manifested by an acute or subacute onset with encephalopathy (behavioral abnormalities or conscious disturbance), as defined by the International childhood multiple sclerosis study group (International Pediatric MS Study Group, IPMSSG).

Neuromyelitis optica (neuromyelitis optica, NMO) is an acute or subacute demyelinating lesion in which the optic nerve is affected simultaneously or sequentially with the spinal cord. The disease is first described by Devic (1894) and is characterized clinically by acute or subacute onset of blindness, either monocular or binocular, followed by transverse or ascending myelitis a few days or weeks before or after it, and is later referred to as Devic disease or Devic syndrome. Neuromyelitis optica was also recorded in china, catalog for rare diseases of the first group, 2018.

There is a continuing need in the art to develop medicaments for the alleviation, alleviation or treatment of demyelinating diseases of the nervous system.

Glucocorticoids have been used in the treatment of multiple sclerosis and acute disseminated encephalomyelitis. Representative glucocorticoids are methylprednisolone, prednisone, etc. (see Myhr KM et al Corticosteroids in the treatment of multiple sclerosis, acta Neurol Scand 2009:120 (suppl. 189): 73-80). However, as hormonal drugs, glucocorticoids have allergic reactions in large amounts for short periods of time; and has great side effects including muscular atrophy, obesity, hypertension, hyperlipidemia, increased urine glucose, osteoporosis and the like after long-term administration. Thus, there remains a need to develop additional drugs to treat central nervous system demyelinating diseases instead of glucocorticoids, without the side effects of glucocorticoids.

Vaccinia virus-induced inflammation rabbit skin extract is an active substance extracted from the skin of a rabbit that is induced to be inflamed after inoculation with vaccinia virus. Such vaccinia virus-induced inflammation rabbit fur extract is commercially available under the trade name Lepalvir (Lepalvir) for pain treatment. Vaccinia virus-induced inflammation rabbit skin extract has proven to be clinically safe and does not produce the above side effects. Furthermore, WO2020/211009 discloses the use of vaccinia virus-induced inflammatory rabbit fur extract for the treatment of hematopoietic lesions; WO 2020/248240 discloses the use of vaccinia virus-induced inflammatory rabbit fur extracts for the treatment of cancer, the entire contents of which are incorporated herein by reference.

Experimental autoimmune encephalitis (experimental autoimmune encephalitis, EAE) is an effective common model for the current study of multiple sclerosis and has been widely used in the study of multiple sclerosis pathogenesis and the exploration of therapeutic drugs (h.levy et al, characterization of brain lesions in a mouse model of progressive multiple sclerosis, experimental Neurology 226 (2010) 148-158).

TNF-alpha and IL-6 are important inflammatory factors in organisms, and can be produced by a plurality of cells such as T cells, B cells, dendritic cells, fibroblasts, smooth muscle cells and the like, but are mainly mononuclear-macrophages. IL-6, an early inflammatory acute protein, induces T cells to differentiate towards Th17, initiating chronic tissue damage. IL-6 cooperates with TNF-alpha to co-participate in and exacerbate the inflammatory response of EAE. Studies have shown that at active MS lesions, the levels of a range of inflammatory cytokines are elevated, including IL-1. Beta., TNF-. Alpha.and IL-6 (Schonrock LM et al, interlukin-6 expression in human multiple sclerosis lesions.Neurosci Lett.2000;294:45-8; and Hofman FM et al, tumor necrosis factor identified in multiple sclerosis brain. J Exp Med.1989; 170:607-12). Natalizumab (Natalizumab), approved for the treatment of MS, significantly reduces the levels of various inflammatory cytokines such as IL-6 and TNF-alpha in cerebrospinal fluid of MS patients (JEt al, natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid, multiple Sclerosis,2010 Feb;16 (2) 208-217).

Disclosure of Invention

Objects of the present invention include providing a medicament for preventing, alleviating or treating demyelinating diseases of the nervous system. More specifically, the object of the present invention consists in providing a medicament for the prevention, alleviation or treatment of multiple sclerosis or acute disseminated encephalomyelitis.

The technical problem of the present invention is solved by providing vaccinia virus inflammatory rabbit fur extract, preferably immediately readjusted.

In general, the inventors have found that vaccinia virus-induced inflammatory rabbit fur extracts are effective in preventing, treating or alleviating demyelinating diseases of the nervous system, in particular demyelinating diseases of the central nervous system, such as multiple sclerosis or acute disseminated encephalomyelitis. Furthermore, the inventors have unexpectedly found that vaccinia virus-induced inflammation rabbit skin extract is better than prednisone approved for use in treating the disease. Such an effect is surprising, as prednisone therapy has been widely used in the clinical treatment of multiple sclerosis.

In one aspect, the invention relates to the use of vaccinia virus-induced inflammatory rabbit fur extract in the manufacture of a medicament for preventing or treating a demyelinating neurological disease in a patient. In one aspect, the invention relates to vaccinia virus-induced inflammatory rabbit fur extracts for use in preventing or treating a demyelinating neurological disease in a patient. In one aspect, the invention relates to a method of preventing or treating a demyelinating neurological disease in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a vaccinia virus-induced inflammatory rabbit skin extract.

In one aspect, the invention relates to the use of vaccinia virus-induced inflammatory rabbit fur extract in the manufacture of a medicament for restoring neural function in a patient suffering from a demyelinating neurological disease. In one aspect, the invention relates to vaccinia virus-induced inflammatory rabbit fur extracts for restoring neural function in patients suffering from demyelinating diseases of the nervous system. In one aspect, the invention relates to a method of restoring nerve function in a patient suffering from a demyelinating neurological disease, the method comprising administering to the patient a therapeutically effective amount of vaccinia virus-induced inflammatory rabbit skin extract.

In one aspect, the invention relates to the use of vaccinia virus-induced inflammatory rabbit fur extract in the manufacture of a medicament for reducing or alleviating inflammation or lowering inflammatory cytokine levels in a patient suffering from a demyelinating neurological disease. In one aspect, the invention relates to vaccinia virus-induced inflammatory rabbit fur extracts for use in reducing or alleviating inflammation or reducing inflammatory cytokine levels in a patient suffering from a demyelinating neurological disease. In one aspect, the invention relates to a method of reducing or alleviating inflammation or lowering inflammatory cytokine levels in a patient suffering from a demyelinating neurological disease, the method comprising administering to the patient a therapeutically effective amount of vaccinia virus-induced inflammatory rabbit fur extract. In this aspect, the extract can reduce inflammatory cytokine levels in the blood, spleen, lesion or cerebrospinal fluid of the patient. In this aspect, the reduction or alleviation of inflammation is achieved by reducing inflammatory cytokines, e.g. reducing inflammatory cytokine levels in the blood, spleen, lesion or cerebrospinal fluid of said patient

The demyelinating neurological disease may be a demyelinating neurological disease characterized by or associated with elevated levels of inflammatory cytokines, such as IL-6 or TNF-alpha.

Inflammatory cytokines, and pro-inflammatory cytokines are used interchangeably and are the generic term for a series of cytokines that promote inflammation. The inflammatory cytokine may be an Interleukin (IL) or Tumor Necrosis Factor (TNF), such as IL-6 or TNF-alpha.

In one aspect, treatment of a demyelinating disease of the nervous system is achieved by alleviating or reducing inflammation in a patient. In one aspect, treatment of demyelinating diseases of the nervous system is achieved by reducing inflammatory cytokine levels, such as IL-6 or TNF-alpha levels.

Preferably, the demyelinating neurological disease is multiple sclerosis.

In one aspect, the nervous system demyelinating disease comprises a central nervous system demyelinating disease or a peripheral nervous system demyelinating disease, preferably a central nervous system demyelinating disease.

In one aspect, the demyelinating neurological disease includes multiple sclerosis, neuromyelitis optica, acute disseminated encephalomyelitis, acute hemorrhagic white matter encephalitis, diffuse sclerosis (Schilder disease) or concentric sclerosis (Balo disease), preferably multiple sclerosis or acute disseminated encephalomyelitis, more preferably multiple sclerosis. In one aspect, the disease is multiple sclerosis. In another aspect, the disease is acute disseminated encephalomyelitis.

In one aspect, the site of a lesion in a demyelinating neurological disease includes the white matter, optic nerve, spinal cord, brain stem, or cerebellum.

In one aspect, restoring neural function includes improving, alleviating, or eliminating the following symptoms: sensory loss or abnormalities, muscle weakness, blurred vision, enhanced reflex, cramping, difficulty in movement, ataxia, tremor of the limbs, dysphagia, nystagmus, eye paralysis, optic neuritis, fatigue, compound vision, incontinence, thought disorder or cognitive disorder.

In one aspect, the demyelinating neurological disease is multiple sclerosis, selected from the following types: clinical single syndrome (CIS), relapsing Remitting (RRMS), secondary Progressive (SPMS), primary Progressive (PPMS), or Progressive Recurrent (PRMS).

In one aspect, vaccinia virus-induced inflammatory rabbit skin extract may be used as the sole active ingredient for the treatment of neurological demyelinating diseases. In this aspect, vaccinia virus-induced inflammatory rabbit skin extract may be used as the sole active ingredient in the preparation of a medicament for treating a neurological demyelinating disease or restoring neurological function in a patient suffering from a neurological demyelinating disease. In a method of treating a demyelinating disease of the nervous system in a patient or in a method of restoring nerve function in a patient suffering from a demyelinating disease of the nervous system, vaccinia virus-induced inflammation rabbit fur extract may be administered to the patient as the sole active ingredient. By "sole active ingredient" is meant that the vaccinia virus-induced inflammatory rabbit fur extract is not used with other nervous system demyelinating disease treatment agents, administered to a patient, or prepared for a medicament. The other nervous system demyelinating disease treatment drug may be a glucocorticoid like drug, such as methylprednisolone or prednisone. Those skilled in the art will appreciate that the combined administration of two agents to a patient and the resulting increase in therapeutic effect does not mean that the administration of both agents alone can achieve a therapeutic effect separately. For example, the use of the extract of the present invention with a glucocorticoid drug may result in an improved therapeutic effect of the glucocorticoid drug, but this does not mean that the extract of the present invention itself would be expected to have a therapeutic effect by those skilled in the art. Furthermore, the combined use of the two drugs still does not solve the side effects of the glucocorticoid drugs themselves. Indeed, the inventors have surprisingly found that vaccinia virus-induced inflammation rabbit fur extracts alone achieve better therapeutic effects than glucocorticoids alone, while avoiding significant side effects of glucocorticoids.

In one aspect, the invention relates to a pharmaceutical composition comprising a vaccinia virus-induced inflammatory rabbit fur extract and optionally a pharmaceutically acceptable carrier, adjuvant or excipient. In one aspect of the invention, the pharmaceutically acceptable carriers, excipients or excipients are those that formulate the medicament into an oral formulation or injection. In one aspect, the vaccinia virus-induced inflammatory rabbit fur extract is formulated into an oral formulation or injection, preferably intramuscular or intravenous injection. In one aspect, the vaccinia virus-induced inflammatory rabbit fur extract is immediately readiness. Accordingly, the present invention also relates to the use of the pharmaceutical composition for treating a demyelinating disease of the nervous system, or for restoring nerve function in a patient suffering from a demyelinating disease of the nervous system. The invention also relates to the use of vaccinia virus-induced inflammation rabbit skin extract in the preparation of the pharmaceutical composition.

In one aspect, the vaccinia virus-induced inflammatory rabbit fur extract is immediately readiness.

In one aspect, the vaccinia virus-induced inflammatory rabbit fur extract is formulated into an oral formulation or injection, preferably an intramuscular injection or intravenous injection.

In one aspect, the patient is a mammal, preferably a human.

In one aspect, the vaccinia virus-induced inflammatory rabbit fur extract is administered to a patient, such as a human, in an amount of 0.05U/kg to 50U/kg, preferably 0.1U/kg to 10U/kg, more preferably 0.5U/kg to 5U/kg.

In one aspect, the medicament is prepared comprising 3U to 3000U, preferably 6U to 600U, more preferably 30U to 300U of said vaccinia virus-induced inflammatory rabbit fur extract.

In one aspect, the vaccinia virus-induced inflammatory rabbit fur extract (preferably, fabulous) is administered to a patient, preferably, a human, in an amount of 0.05U/kg to 50U/kg, preferably, 0.1U/kg to 10U/kg, more preferably, 0.5U/kg to 5U/kg. For example, the vaccinia virus-induced inflammatory rabbit skin extract is administered to a patient, preferably a human, in an amount selected from the group consisting of: 0.05U/kg, 0.06U/kg, 0.07U/kg, 0.08U/kg, 0.09U/kg, 0.1U/kg, 0.2U/kg, 0.3U/kg, 0.4U/kg, 0.5U/kg, 0.6U/kg, 0.7U/kg, 0.8U/kg, 0.9U/kg, 1U/kg, 1.5U/kg, 2U/kg, 2.5U/kg, 3U/kg, 3.1U/kg, 3.2U/kg, 3.3U/kg, 3.4U/kg, 3.5U/kg, 3.6U/kg, 3.7U/kg, 3.8U/kg, 3.9U/kg, 4U/kg, 4.5U/kg, 4.8U/kg 5U/kg, 5.5U/kg, 6U/kg, 6.5U/kg, 7U/kg, 7.5U/kg, 8U/kg, 8.5U/kg, 9U/kg, 9.5U/kg, 10U/kg, 11U/kg, 12U/kg, 13U/kg, 14U/kg, 15U/kg, 16U/kg, 17U/kg, 18U/kg, 19U/kg, 20U/kg, 25U/kg, 30U/kg, 35U/kg, 40U/kg, 45U/kg, 50U/kg, and ranges bordered by these numbers. Those skilled in the art know that for the administered amount, the dose of human (U/kg or mg/kg) =the dose of mouse (U/kg or mg/kg)/12.3; or human dose (U/kg or mg/kg) =mouse dose (U/kg or mg/kg) ×0.08. The above dosage may be an effective amount to treat the above-mentioned disease in the patient. In one aspect, the vaccinia virus-induced inflammatory rabbit fur extract is administered by injection, such as intramuscular injection or intravenous injection, at the dosages described above.

In one aspect of the invention, the medicament or pharmaceutical composition is prepared comprising a vaccinia virus-induced inflammatory rabbit fur extract comprising 3U to 3000U, preferably 6U to 600U, more preferably 30U to 300U. The medicament or pharmaceutical composition is for administration to a human, such as an adult. The average weight of an adult is, for example, 60kg. Accordingly, the amount of vaccinia virus-induced inflammation rabbit fur extract included in the medicament prepared according to the present invention is, for example, 3U, 4U, 5U, 6U, 7U, 8U, 9U, 10U, 15U, 20U, 25U, 30U, 35U, 40U, 42U, 44U, 45U, 46U, 47U, 48U, 49U, 50U, 55U, 60U, 65U, 70U, 80U, 90U, 100U, 120U, 150U, 160U, 170U, 180U, 190U, 192U, 194U, 195U, 196U, 198U, 200U, 220U, 240U, 260U, 280U, 300U, 350U, 400U, 500U, 600U, 700U, 800U, 900U, 1000U, 1500U, 2000U, 2500U, 3000U, and ranges bordered by these numbers. In one aspect, the medicament or pharmaceutical composition is prepared as an injection, such as an intramuscular injection or an intravenous injection. In one aspect, the medicament or injection is an indivisible fixed dose. In one aspect, the medicament or injection is not divisible into smaller doses within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days. In one aspect, the medicament or injection is administered only once within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days.

In one aspect, the vaccinia virus-induced inflammatory rabbit skin extract is administered to the patient every 6-72 hours, preferably 12-48 hours, more preferably 24-36 hours, more preferably 24 hours.

In one aspect, the regimen is administered to the patient three times daily, twice daily, once daily for two days, once every three days, once every four days, once every five days, once every six days, once every week, once every two weeks, once every three weeks, and once every month. For example, the extract of the present invention may be administered to a patient once daily.

In one aspect, the extract of the invention is administered to a patient for at least 24 months, at least 12 months, at least 6 months, at least 2 months, at least 1 month, at least 3 weeks, at least 2 weeks, at least 10 days, at least 7 days, at least 5 days, at least 2 days, or at least 1 day.

As used herein, "vaccinia virus-induced inflammation rabbit skin extract (extract from rabbit skin inflamed by vaccinia virus)" refers to an extract containing an active substance extracted from inflamed rabbit skin inoculated with vaccinia virus, for example, by leaching, purifying, refining, etc. Such extracts are typically yellow or pale yellow liquids, but may also be made into solids by drying methods. An injection of this vaccinia virus-induced inflammatory rabbit fur extract is commercially available under the trade name Lepalvir. The vaccinia virus-induced inflammation rabbit fur extract of the present invention may comprise a peptide. For example, it has been found that the extract may contain naturally occurring peptides (i.e., peptides that are not added in addition). The peptide may be a short peptide. WO2013173941 describes short peptides isolated from vaccinia virus-induced inflammatory rabbit fur extracts. Thus, in this aspect, the vaccinia virus-induced inflammatory rabbit fur extract of the present invention may not be a non-protein extract.

In the preparation of the extract of the invention, the preparation method comprises extracting inflamed rabbit fur fragments after vaccinia virus inoculation with an aqueous phenol solution, wherein the extraction is preferably performed using an aqueous phenol solution having a phenol concentration of about 1% -10%, preferably about 2% -5%, more preferably about 2% or about 3% at a temperature below about 12 ℃, for example about 0-10 ℃, preferably about 2-8 ℃, more preferably about 3-6 ℃, more preferably about 4 ℃. The production process further comprises adsorbing the extract treated with the phenol aqueous solution with an adsorbent (e.g., activated carbon) and performing desorption under alkaline conditions, wherein the adsorption is preferably performed under acidic conditions (e.g., about pH3 to 6, more preferably about pH4 to 5, more preferably about pH 4.5), and the alkaline conditions of the desorption are about pH9 to 12, preferably about pH10 or pH11.

In one aspect, the vaccinia virus-induced inflammatory rabbit fur extract or readiness can be prepared by a method comprising the steps of:

(1) Collecting inflamed rabbit skin inoculated with vaccinia virus, fragmenting the rabbit skin, and extracting with an extraction solvent to obtain a solution A;

(2) Carrying out acid and heating treatment on the solution A to obtain a solution B;

(3) Performing alkali and heating treatment on the solution B to obtain a solution C;

(4) Adsorbing and filtering the solution C under an acidic condition, and desorbing under an alkaline condition to obtain a solution D;

(5) Neutralizing and heating the solution D to obtain a solution E;

(6) Concentrating the solution E to obtain the extract; and

(7) Optionally mixing the extract with pharmaceutically acceptable carrier, adjuvant or excipient.

In one aspect, in step (1), rabbits are inoculated with vaccinia virus, the poxed skin is collected, the skin is fragmented, phenol aqueous solution is added, soaked at less than about 12 ℃ (e.g., about 0-10 ℃, preferably about 2-8 ℃, more preferably about 3-6 ℃, more preferably about 4 ℃) for at least about 12 hours (e.g., about 24-90 hours, preferably about 48-72 hours, more preferably about 70 or about 72 hours), centrifuged to obtain a supernatant, and solution a is filtered. The phenol concentration in the aqueous phenol solution is about 1% to 10%, preferably about 2% to 5%, more preferably about 2% or about 3%.

In one aspect, in step (2), solution A is made acidic (e.g., about pH4-6, more preferably about pH4.5-5.5, more preferably about pH 5) with an acid (e.g., hydrochloric acid), heated (e.g., at about 90-100deg.C, preferably about 95deg.C for at least about 10 minutes, e.g., about 20-50 minutes, preferably about 30-40 minutes), optionally cooled (e.g., to below about 50deg.C, preferably below about 30deg.C), and the supernatant is obtained by centrifugation, and filtered to obtain solution B. The step (2) may be performed under a nitrogen atmosphere.

In one aspect, in step (3), solution B is made basic (e.g., about pH8-10, more preferably about pH8.5-9.5, more preferably about pH9 or about pH 9.2) with a base (e.g., sodium hydroxide), heated (e.g., at about 90-100 ℃, preferably about 95 ℃ for at least 10 minutes, e.g., about 30-50 minutes, preferably about 30-40 minutes), optionally cooled (e.g., to less than about 50 ℃, preferably less than about 30 ℃) and filtered to obtain solution C. The step (3) may be performed under a nitrogen atmosphere.

In one aspect, in step (4), solution C is brought to acidity (e.g., about pH3-6, more preferably about pH4-5, more preferably about pH 4.5) with an acid (e.g., hydrochloric acid), an adsorbent (e.g., activated carbon) is added thereto for soaking (e.g., for at least about 1 hour, preferably about 2-10 hours, more preferably about 4 hours, with stirring), after which the solution is removed and the adsorbent containing the active ingredient is collected. Subsequently, the above-described adsorbent is added to an eluent (e.g., water), the pH is adjusted to be alkaline (e.g., about pH9-12, preferably about pH10 or pH 11) with a base (e.g., sodium hydroxide) to separate the active ingredient from the adsorbent (e.g., stirring for at least about 1 hour, preferably 2-10 hours, more preferably 4 hours, followed by filtration and washing the adsorbent with water) to obtain solution D. The step (4) may be performed under a nitrogen atmosphere.

In one aspect, in step (5), solution D is neutralized to a weak acidity (e.g., about pH5.5-6.6, preferably about pH 6) with an acid (e.g., hydrochloric acid) to provide solution E. Preferably, the step (5) may be performed under aseptic conditions.

In one aspect, in step (6), the solution E is concentrated (e.g., concentrated under reduced pressure, preferably concentrated by evaporation under reduced pressure, e.g., at about 50℃ to about 70℃, preferably about 54℃ to about 56℃), followed by filtration to obtain an extract containing the active ingredient. The step (6) may be performed under a nitrogen atmosphere.

Those skilled in the art will appreciate that the extracts of the invention may also be obtained by inoculating other animal tissues with vaccinia virus. For example, in the present invention, an extract of inflamed tissue inoculated with vaccinia virus may be used. The tissue may be from a tissue of a mammal, which may include companion animals, laboratory animals, farm animals, such as rabbits, cattle, horses, sheep, goats, monkeys, mice, pigs. The tissue may be skin.

Detailed Description

Unless otherwise indicated, all scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Example methods and materials are described below, and equivalents thereof may be used. All publications and other references mentioned herein are incorporated by reference in their entirety.

The following examples are provided to further illustrate the invention. The following examples are not intended to limit the scope of the invention for any reason.

Examples

EXAMPLE 1 therapeutic Effect of Lishizai on multiple sclerosis (EAE model)

1. Purpose of test

Research on the therapeutic effects of readjustment on multiple sclerosis (EAE model)

2. Test method

SPF grade C57BL/6 mice, 18-22g,250 males. After the quarantine was completed, all the other mice except 16 negative control groups were injected with 0.2mL of MOG35-55 emulsifier antigen (MOG 35-55 injection amount was 200 ug/min) at 3 points of the back skin portion, and 1/3 of each point was injected. Pertussis toxin was injected at 200 ng/i.p. on days 1, 3. Mice screened for an approximate neurological score of 2 were randomly assigned to model control, prednisone acetate, "immediately readjusted" low, medium, and high dose groups, 16 mice/group. The corresponding test drugs were administered daily to the abdominal cavity after the grouping, and the model control group was administered with an equivalent amount of physiological saline 1 time/d. Half of the mice were randomized for each group for testing on day 21 and day 28 of dosing.

3. Experimental materials

3.1 test drug

Vaccinia virus induced inflammation rabbit fur extract ("Lishishi" stock solution, abbreviated LZS).

3.2 Positive control

Prednisone acetate injection (PA for short).

4. Grouping of laboratory animals

Animals were screened for neurological scores of approximately 2 points, and randomly assigned to 16 mice/group, model control, prednisone acetate, "immediately readjusted" low (10U/Kg), medium (20U/Kg), high (40U/Kg).

5. Pharmaceutical formulation

5.1 preparation of emulsifier:

5mg of the MOG35-55 dry powder was dissolved in PBS to 2.5mL to give a solution with a concentration of 2 mg/mL. MOG35-55 solution was mixed with the same volume of complete Freund's adjuvant (1:1), and 10mg/mL of tubercle bacillus was added to the adjuvant to form an emulsifier.

5.2 high dose LZS (4U/mL):

the LZS stock solution was diluted to 4U/ml with physiological saline.

Dose LZS (2U/mL) in 5.3:

the high dose LZS is diluted 2 times by normal saline to prepare 2U/ml.

5.4 Low dose LZS (1U/mL):

the high dose LZS is diluted 4 times by normal saline to prepare 1U/ml.

5.5 Prednisone Acetate (PA):

taking prednisone acetate injection, and diluting to 0.7mg/mL with normal saline.

5.6 Pertussis Toxin (PTX):

PTX was dissolved in physiological saline and the concentration was adjusted to 2. Mu.g/mL.

6. The molding method comprises the following steps:

all mice except the negative control group were injected with 0.2mL of emulsifier per mouse (i.e., MOG35-55 was injected at 200 ug/dose). Day 1, mice were injected subcutaneously with 0.2mL of antigen formulation at 3 points on the back, one on the mid-line of the shoulder, and two on either side of the lower mid-line of the back. Each site was injected 1/3. 200 ng/pertussis toxin was intraperitoneally injected on days 1, 3. On day 14 of molding, mice with animal nerve function scores of about 2 were screened, and randomly divided into a model control group, a prednisone acetate group, a "quick-fit" low (10U/Kg), a medium (20U/Kg), a high-dose group (40U/Kg), and 16 animals/group.

7. The administration method comprises the following steps:

the corresponding test drugs were administered to the abdominal cavity every day after the grouping, and the model control group was administered with an equal amount of physiological saline 1 time/day. On days 21 and 28 of dosing, 8 mice per group were tested:

table 1 group, dose and dosing regimen

7. Detection index

The general clinical manifestations of the animals were observed daily, and the body weights of the animals were measured 1 time per week. The improvement was calculated by scoring the neurological function 1 time per week.

Degree of improvement (%) = (post-dose neurological score-pre-dose neurological score)/pre-dose neurological score x 100%

TABLE 2 neurological score (Kono 5 method)

8. The data statistics method comprises the following steps:

all data adoptionRepresenting, statistical analysis using SPSS 21.0 software; the variance of the data of the measurement data is uniform, or the variance of the data is uniform after conversion, a single factor variance analysis method of pairwise comparison between groups is adopted; and if the variance of the converted data is still uneven, carrying out statistical analysis by adopting rank sum test. Test level α=0.05.

9. Experimental results

9.1 general observations and body weight (see table 3):

the animals in each group generally have no abnormal performance in daily observation, the weight of each group is normally increased, no statistical difference (P is more than 0.05), and no animal death exists in the experimental process.

9.2 neurological score (see table 4):

the average neurological scores of the LZS low (10U/Kg), medium (20U/Kg), high (40U/Kg) and prednisone acetate mice all tended to decrease over the 7-28 days of dosing compared to the model control. The decrease in function scores of both LZS medium and high mice was statistically different (P < 0.05) at 14 days of administration, with improvement of 35.3% and 55.6%, respectively. The decrease in function scores of both LZS medium and high mice was statistically different (P < 0.05) at 21 days of administration, with 41.2% and 55.6% improvement, respectively. The mice in the low, medium and high LZS groups had statistically different functional scores (P < 0.05) at 28 days of administration, and improved at 38.9%, 52.9% and 55.6% respectively, which were all better than 27.8% of the prednisone acetate group.

EXAMPLE 2 Lishizhi for Effect on inflammatory cytokines in multiple sclerosis

After blood collection was performed on each group of animals in example 1, spleens were collected and stored in a frozen state. Flow cytometry was used to detect the proportion of T cell subsets (Th 1, th17, treg, CD4+IL-10+T cells) in spleen, and ELISA method was used to detect the expression levels of spleen IL-6 and TNF-alpha.

IL-6 level: model mice had no statistical difference (P > 0.05) in IL-6 at 23 days lower than the placebo group and IL-6 at 30 days higher than the placebo group. The IL-6 levels of the positive control group and the LZS low and medium dose groups were significantly reduced (P < 0.05) after 30 days of administration.

TNF- α levels: model mice had a statistical difference in TNF- α levels at 23 days of dosing compared to the placebo group (P < 0.04), and at 30 days of dosing compared to the placebo group, but no statistical difference (P > 0.05). TNF-alpha levels were significantly reduced in the LZS-dosed group (P < 0.05) for 30 days of dosing.

The results of this study suggest that LZS has the effect of reducing IL-6 and TNF- α. In addition, there were no statistical differences (P > 0.05) in LZS-dose groups of mice Th1, th17, treg, cd4+il-10+tcells (%), CD3 (%), CD4 (%), CD8 (%) (data not shown).

In conclusion, immunization of C57BL/6 mice with MOG35-55 successfully induced an EAE model of autoimmune disease. LZS has improved functional scores in mice with EAE models, possibly acting on IL-6 and TNF- α inflammatory factors.

Claims (14)

1. Use of vaccinia virus-induced inflammatory rabbit fur extract in the manufacture of a medicament for preventing or treating a demyelinating neurological disease in a patient.
2. The use of claim 1, wherein the medicament is for restoring nerve function in a patient suffering from a demyelinating disease of the nervous system.
3. Use of vaccinia virus-induced inflammatory rabbit fur extract in the manufacture of a medicament for reducing or alleviating inflammation or lowering inflammatory cytokine levels in a patient suffering from a demyelinating neurological disease.
4. The use of any one of claims 1-3, wherein the neurological demyelinating disease comprises a central or peripheral nervous system demyelinating disease.
5. The use according to any one of claims 1-4, wherein the demyelinating neurological disease comprises multiple sclerosis, neuromyelitis optica, acute disseminated encephalomyelitis, acute hemorrhagic white matter encephalitis, diffuse sclerosis (Schilder disease) or concentric circular sclerosis (Balo disease), preferably multiple sclerosis or acute disseminated encephalomyelitis.
6. The use of any one of claims 1-5, wherein the site of a lesion in a demyelinating disease of the nervous system comprises white matter, optic nerve, spinal cord, brain stem or cerebellum.
7. The use of claim 2, wherein restoring neural function comprises improving, alleviating, or eliminating the following symptoms: sensory loss or abnormalities, muscle weakness, blurred vision, enhanced reflex, cramping, difficulty in movement, ataxia, tremor of the limbs, dysphagia, nystagmus, eye paralysis, optic neuritis, fatigue, compound vision, incontinence, thought disorder or cognitive disorder.
8. The use of any one of claims 1-7, wherein the neurological demyelinating disease is multiple sclerosis of a type selected from clinical single syndrome (CIS), relapsing Remitting (RRMS), secondary Progressive (SPMS), primary Progressive (PPMS) or Progressive Recurrent (PRMS).
9. The use of claim 3, wherein the inflammatory cytokine is selected from IL-6 or TNF- α.
10. The use of any one of claims 1-9, wherein the vaccinia virus-induced inflammatory rabbit fur extract is immediately readiness.
11. The use according to any one of claims 1 to 10, wherein the vaccinia virus-induced inflammatory rabbit fur extract is formulated into an oral preparation or injection, preferably intramuscular injection or intravenous injection.
12. The use of any one of claims 1-11, wherein the patient is a human.
13. The use of any one of claims 1-12, wherein the vaccinia virus-induced inflammatory rabbit fur extract is administered to the patient in an amount of 0.05U/kg to 50U/kg, preferably 0.1U/kg to 10U/kg, more preferably 0.5U/kg to 5U/kg.
14. The use of any one of claims 1-13, wherein said medicament comprises 3U to 3000U, preferably 6U to 600U, more preferably 30U to 300U of said vaccinia virus-induced inflammatory rabbit fur extract.